| Document |
Document Title |
|
WO/2006/003194A1 |
Chiral, secondary amines of the formula (I) or (II), where R01, R02 and R03 are each, independently of one another, C1-C4-alkyl, R04 is C1-C4-alkyl, C1-C4-alkoxymethyl or C1-C4-alkoxyethyl, and * indicates predominantly one configuration...
|
|
WO/2006/004923A2 |
The present invention provides enantiomerically pure (R)-(-)-tomoxetine (S)-(+)-mandelate and atomoxetine HCI. The present invention further provides enantiomerically pure (R)-(-)-tomoxetine (S)-(+)-mandelate prepared from racemic 5 tomo...
|
|
WO/2006/004977A2 |
The present invention provides a process for the optical resolution of racemic tomoxetine under reaction conditions that improve reaction yields and optical purity. The invention also provides an epimerization process for the (S)-(+) ena...
|
|
WO/2006/001463A1 |
Compounds of the general formula (I); their salts, N-oxides and solvates; prodrugs thereof; and medicines comprising these. (I) [wherein each of the ring A and ring D is a substituted or unsubstituted cyclic group; each of E and G is a b...
|
|
WO/2005/123018A1 |
The invention relates to the derivatives of the m-aminophenol according to formula (I), and to agents containing said derivative for oxidatively dyeing keratin fibers, especially human hair. The invention also relates to the use of said ...
|
|
WO/2005/123659A1 |
The invention relates to a method of synthesising a compound having formula (I) and to the use thereof for the synthesis of ivabradine and the pharmaceutically-acceptable acid addition salts and hydrates of same.
|
|
WO/2005/121067A1 |
The invention relates to a method for cosmetic treatment of wrinkled skin, comprising topical application to the skin of a composition comprising at least one((dialkylamino)alkoxy) ethanol ester of formula (I). The invention also relates...
|
|
WO/2005/120152A2 |
The present invention is directed to compositions comprising cationic with alkyl side chains from about 10 to about 20 carbon atoms having more than a single site of unsaturation, liposomes and nucleic acid-lipid particles comprising the...
|
|
WO/2005/118523A1 |
A compound of formula (I) wherein R1, R2, R3, Ra and R5 are as defined in the specification, processes for their production, their uses, in particular in transplantation, and pharmaceutical compositions containing them.
|
|
WO/2005/118525A1 |
The present invention relates to a process (Mukaiyama Aldol reaction) for thepreparation of compounds of formula (I) wherein R1 is C1-4 alkyl, C3-6 cycloalkyl-C1-4 alkyl or aryl-C1-4 alkyl; R2 is C1-4 alkyl, benzyl, substituted benzyl or...
|
|
WO/2005/115994A1 |
Substituted pyrazinecarboxylic acid anilide derivatives represented by the general formula (I) or salts thereof; intermediates of them; pesticides (such as insecticides and acaricides) for agricultural and horticultural use, containing t...
|
|
WO/2005/116054A1 |
Disclosed are highly convergent processes for preparing compounds of formula (I), which compounds are potent active agents for the treatment of hepatitis C virus (HCV) infection. The disclosed processes use SNAr-type coupling reactions b...
|
|
WO/2005/115970A1 |
Disclosed is a p-terphenyl compound represented by the following general formula (1) or (2). Also disclosed is a photosensitive body for electrophotography containing such a compound. This p-terphenyl compound provides a charge-transport...
|
|
WO/2005/117443A2 |
A method for selecting a certificate for the authentication of an application associated with a distributor, the method comprising accessing (104) application metadata comprising an identifier (108) of the distributor and extracting (106...
|
|
WO/2005/113481A1 |
Provided are processes for the preparation of (R)-SLB.D-DBTA salt and levalbuterol hydrochloride. Also provided are levalbuterol hydrochloride degradation products and processes for preparing them. Pharmaceutical compositions comprising ...
|
|
WO/2005/113487A2 |
The invention is directed to novel compounds that are used in the formation of polyurea compositions, including one-part and two-part polyurea compositions. The invention is also directed to polyureas formed from such compounds, cross-li...
|
|
WO/2005/113506A1 |
The invention provides compounds, pharmaceutical compositions comprising such compounds and methods of using such compounds to treat or prevent diseases or disorders associated with the activity of the Peroxisome Proliferator-Activated R...
|
|
WO/2005/113482A1 |
The invention is directed to levalbuterol HC1 Form B and methods of making the same.
|
|
WO/2005/113483A2 |
The invention is directed to processes for making levalbuterol HC1 Polymorph A from by suspending or forming a first slurry of (R)-SLB(D)-DBTA in at least a first organic solvent, adding HC1 to the suspension or slurry of the solid (R)-S...
|
|
WO/2005/110969A1 |
The invention relates to a method for the continuous production of an amine by reacting a primary or secondary alcohol, aldehyde and/or ketone with hydrogen and a nitrogen compound, selected from the group containing ammonia and primary ...
|
|
WO/2005/111050A2 |
This invention relates to phosphoramidite compounds and catalyst complexes which can be used to provide enantioselective reactions including hydroamination reactions, etherification reactions and conjugate addition reactions and allylic ...
|
|
WO/2005/108409A2 |
Compounds of the formula (I) or (I'), where R1 is a hydrogen atom or C1-C4-alkyl and R'1 is C1-C4-alkyl; X1 and X2 are each, independently of one another, a secondary phosphine group; R2 is hydrogen, R01R02R03Si-, C1-C18 -acyl substitu...
|
|
WO/2005/100324A1 |
Compounds of the following formula (I) wherein R1 R2, n, Ar1 and A2 are as defined in the specification, in vivo-hydrolysable precursors thereof, pharmaceutically acceptable salts thereof, the use in therapy and pharmaceutical compositio...
|
|
WO/2005/097731A2 |
The present invention relates to ionic liquid comprising an anion and a cation wherein the cation is a primary, secondary or tertiary ammonium ion containing a protonated nitrogen atom.
|
|
WO/2005/097093A1 |
Compounds having the following structure: (I) including stereoisomers, prodrugs, and pharmaceutically acceptable salts thereof, wherein R1, R2a, R2b, R3, R4, R5a, R5b, L1, L2 and n are as defined herein. Pharmaceutical compositions conta...
|
|
WO/2005/097087A2 |
Merged compounds of ion channel modulating compounds, including, for example, merged compounds of the ion channel modulating compound of the following formula: (I) are described herein, as well as methods of making and using such merged ...
|
|
WO/2005/099312A2 |
The present invention relates to triarylamine compounds of formula (I) or (III): Wherein the variables n, R1, R2, R3 and E are as defined in the claims, commpositions comprising such compounds, and electronic devices and applications com...
|
|
WO/2005/097732A1 |
This invention pertains to novel multiple quaternary ammonium salts and their derivatives represented by the formula: wherein each R1, R'1, R2, R'2, R3, R'3, R4 or R5 is independently selected from the group consisting alkyl, aryl, aralk...
|
|
WO/2005/097773A1 |
The present invention is related to carboxylic acids of Formula (I) and use thereof for the treatment and/or prevention of obesity and/or metabolic disorders mediated by insulin resistance or hyperglycemia, comprising diabetes type I and...
|
|
WO/2005/097203A2 |
Serum protein conjugates of ion channeling modulating compounds, including, for example, serum protein conjugates of the ion channel modulating compound of the following formula (I) are described herein, as well as methods of making and ...
|
|
WO/2005/095324A1 |
A quaternary ammonium compound represented by the general formula (I) or (I'): (I) or (I') wherein A represents C1-4 linear alkyl, C2-4 branched alkyl, hydroxylated C1-4 linear alkyl, or hydroxylated C2-4 branched alkyl; R1 to R3 are the...
|
|
WO/2005/091754A2 |
Novel compounds and methods useful in the control, treatment, and prevention of fungal activity.
|
|
WO/2005/092836A1 |
A compound of the formula (I) wherein the variables X1, X2, B, D, R1 to R7.including R3', p, y, q, and z, are as defined or a pharmaceutically acceptable salt, solvate, enantiomer, racemate, diastereomer or mixtures thereof, useful for t...
|
|
WO/2005/092317A1 |
The invention provides compounds of formula (I) or a pharmaceutically acceptable ester, amide, solvate or salt thereof, including a salt of such an ester or amide, and a solvate of such an ester, amide or salt. The invention also provide...
|
|
WO/2005/092840A1 |
The invention relates to compounds of formula (1) and to processes for the preparation of, intermediates used in the preparation of, compositions containing and the uses of, such derivatives. The compounds according to the present invent...
|
|
WO/2005/092833A1 |
A production process by which a 1,2-ethanediamine derivative for use as a raw material in producing useful chemical substances including medicines can be industrially advantageously produced at low cost. The process, which is for produci...
|
|
WO/2005/092835A1 |
The present invention relates to inhibitors of serotonin and/or norepinephrine reuptake and specifically provides compounds of formula (I): wherein A is selected from -O- and -S-; X is selected from C1-C8 alkyl, C2-C8 alkenyl, and C4-C8 ...
|
|
WO/2005/090283A1 |
A method of synthesising a compound of formula I: comprising the step of reacting a moiety of formula II: with a moiety of formula III: in compressed carbon dioxide in the presence of a transition metal catalyst and a base, wherein L is ...
|
|
WO/2005/087700A2 |
The present invention discloses bisphenyl compounds of the formula (1): wherein R1, R2, R3, R4, R5, R6, X, Y, W are defined herein after. These compounds are useful as pharmaceuticals.
|
|
WO/2005/085176A1 |
A &pgr -conjugated aromatic ring-containing compound represented by the formula (1) below is relatively stable and useful as a light-emitting material for light from blue-violet region to red region. (1) [In the formula, R1-R6 independen...
|
|
WO/2005/082834A1 |
The present invention relates to a process for the production of severely sterically hindered amino-ether alcohols using a catalyst based on the combination of one or more catalytically active metals supported in a dispersed form on one ...
|
|
WO/2005/081778A2 |
The present invention relates to a process for preparing severely sterically hindered secondary amine ether alcohols and diamine polyalkenyl ethers by reacting a primary amino compound with a polyalkenylether glycol in the presence of a ...
|
|
WO/2005/082835A1 |
Severely sterically hindered secondary aminoether alcohols are prepared by reacting organic carboxylic, organic carboxylic acid halides, acid anhydrides or a ketene with an alkyl, alkaryl or alkylhalo sulfonate to yield a sulfonic. Carbo...
|
|
WO/2005/082837A1 |
Severely sterically hindered secondary aminoether alcohols are prepared by reacting acid anhydrides or organic carboxylic acid halides with S03 to yield a sulfonic carboxylic anhydride compound which is then reacted with a dioxane to cle...
|
|
WO/2005/082838A1 |
À process for the preparation of optically active substituted alpha-indanyl amide derivatives of formula (I), which comprise*: - an asymmetric hydrogenation reaction of an en-amide derivative óf formula (III) in presence of hydrogen ...
|
|
WO/2005/082824A1 |
The invention comprises an enantioselective method of preparing a compound of formula (IV): (a) asymmetric epoxidation of a compound of formula (I) wherein R1 and m are as defined above, with an oxidising agent in the presence of an opti...
|
|
WO/2005/079774A2 |
A drug may be used in the preparation of a medicament for the treatment or prevention of an ophthalmologic disorder, wherein the drug inihibits, antagonizes, or shortcircuits the visual cycle at a step of the visual cycle that occurs o...
|
|
WO/2005/077892A1 |
Novel calcilytic compounds and methods of using them are provided.
|
|
WO/2005/077886A1 |
Novel calcilytic compounds and methods of using them are provided.
|
|
WO/2005/077899A2 |
Compounds of formula (I) wherein A and B are amine-substituted sidechains, Y1 and Y2 form various tricyclic cores, Xa and Xb are C, CH, or N, as defined herein, and Rx is an optional substituent. Compounds and compositions of formula (I)...
|
